RYR1 and short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome: Given the differences in the simvastatin binding modes on RyR1 and HMG-CoA reductase (Supplemental Figure 17), our RyR1-simvastatin structure may provide mechanistic rationale for future therapeutic studies to develop type 1 statin drugs with reduced incidence of SAMS.